review of hers glp 1 reviews consumer reports Novo Nordisk calls out dangers compounded GLP-1s in new ad Remedy Meds vs Hers: GLP-1

10.18553/jmcp.2024.23332 J Manag Care Spec Pharm

Using a target trial emulation framework, researchers analyzed Truveta Data and compared adults with alcohol use disorder (AUD) and either type 2 diabetes or obesity who started a newer GLP-1 RA (semaglutide, tirzepatide) to similar individuals starting alternative medications

A higher mitotic rate (2 mitoses per 10 HPFs) has been noted to correlate with metastasis, but the converse is not necessarily true, and benign-looking lesions still have malignant protentional

Retatrutide: The Prototype Triple Agonist Retatrutide (LY3437943) is a once-weekly acylated peptide developed by Eli Lilly